bendamustine hydrochloride has been researched along with mitoxantrone in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Boehrer, S; Chow, KU; Hoelzer, D; Mitrou, PS; Rummel, MJ; Schneider, B; Seipelt, G; Sommerlad, WD; Weidmann, E | 1 |
| Gores, A; Heymanns, J; Köppler, H; Weide, R | 1 |
| Boehrer, S; Chow, KU; Hoelzer, D; Knau, A; Mitrou, PS; Nowak, D; Ruthardt, M; Weidmann, E | 1 |
| Heymanns, J; Köppler, H; Pandorf, A; Weide, R | 2 |
| Aldaoud, A; Dreyling, M; Haak, U; Hess, G; Heymanns, J; Hiddemann, W; Huber, C; Köppler, H; Losem, C; Schmitz, S; Thomalla, J; Unterhalt, M; Weide, R | 1 |
| Friedberg, JW | 1 |
| Friesenhahn, V; Heymanns, J; Kleboth, K; Köppler, H; Mergenthaler, U; Thomalla, J; Weide, R | 1 |
| Fuss, H; Hallek, M; Hurtz, HJ; Knigge, O; Köppler, H; Losem, C; Reschke, D; Schmitz, S; Weide, R; Weiß, J | 1 |
| Atmar, J; Mullen, E | 1 |
| Cheah, CY; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; McLaughlin, P; Nastoupil, LJ; Neelapu, SS | 1 |
| Caballero, MD; Canales, M; Capote, FJ; Durán, S; Giraldo, P; Gutiérrez, A; López, A; Márquez, JA; Martín, A; Montalbán, C; Peñalver, FJ; Ramírez, MJ; Rodríguez-Caravaca, G; Salar, A; Sánchez, B; Sancho, JM; Terol, MJ | 1 |
| Baldini, L; Balzarotti, M; Boccomini, C; Bolis, S; Chiarenza, A; Ciccone, G; Corradini, P; Evangelista, A; Ferrero, S; Freilone, R; Ladetto, M; Marina Liberati, A; Nassi, L; Novo, M; Puccini, B; Rattotti, S; Rigacci, L; Rusconi, C; Stelitano, C; Tucci, A; Vitolo, U; Volpetti, S | 1 |
1 review(s) available for bendamustine hydrochloride and mitoxantrone
| Article | Year |
|---|---|
Norovirus in immunocompromised patients.
Topics: Abdominal Pain; Aged; Antibodies, Monoclonal, Murine-Derived; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Caliciviridae Infections; Combined Modality Therapy; Disinfection; Female; Fluid Therapy; Gastroenteritis; Hand Disinfection; Humans; Immunocompromised Host; Incidence; Infection Control; Lymphoma, Follicular; Mitoxantrone; Nitrogen Mustard Compounds; Norovirus; Rituximab; Virus Shedding | 2013 |
8 trial(s) available for bendamustine hydrochloride and mitoxantrone
| Article | Year |
|---|---|
Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy | 2002 |
Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Opportunistic Infections; Remission Induction; Survival Analysis | 2004 |
Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Bendamustine Hydrochloride; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Outpatients; Pilot Projects; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Rituximab; Survival Rate; Time Factors; World Health Organization | 2004 |
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome | 2007 |
Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Recurrence; Treatment Outcome | 2012 |
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Communicable Diseases; Hematologic Diseases; Humans; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Rituximab | 2016 |
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Progression-Free Survival; Rituximab; Salvage Therapy | 2019 |
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Consolidation Chemotherapy; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Mitoxantrone; Neoplasm Grading; Progression-Free Survival; Prospective Studies; Remission Induction; Rituximab; Safety; Topoisomerase II Inhibitors | 2021 |
4 other study(ies) available for bendamustine hydrochloride and mitoxantrone
| Article | Year |
|---|---|
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Burkitt Lymphoma; Caspase 7; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cladribine; Complement Activation; Complement System Proteins; Cysteine Proteinase Inhibitors; Doxorubicin; Drug Synergism; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Mitoxantrone; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Rabbits; Rituximab; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bendamustine Hydrochloride; Carrier Proteins; Caspases; Cladribine; Co-Repressor Proteins; Cytochrome c Group; Cytoskeletal Proteins; Down-Regulation; Doxorubicin; Drug Synergism; Enzyme Activation; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Lymphoma; Mitochondrial Proteins; Mitoxantrone; Molecular Chaperones; Nitrogen Mustard Compounds; Nuclear Proteins; Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2003 |
Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Mitoxantrone; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome | 2009 |
Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy | 2009 |